Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 7, 2017; 23(33): 6155-6163
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6155
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6155
Table 4 Treatment regimens resulted in complete remission
| Total | Group A: No chromosome aberration1 | Group B:t(11;18) positive | Group C:Extra copies of MALT1 | |
| n | 103 | 61 | 21 | 21 |
| Treatment | ||||
| Eradication alone | 58 | 44 | 1 | 13 |
| RT alone | 20 | 6 | 14 | 0 |
| Chemotherapy alone | 4 | 1 | 1 | 2 |
| RT and chemotherapy | 2 | 1 | 0 | 1 |
| Eradication and RT | 13 | 5 | 4 | 4 |
| Eradication and chemotherapy | 3 | 2 | 0 | 1 |
| Eradication, RT and chemotherapy | 1 | 0 | 1 | 0 |
| None | 2 | 2 | 0 | 0 |
- Citation: Iwamuro M, Takenaka R, Nakagawa M, Moritou Y, Saito S, Hori S, Inaba T, Kawai Y, Toyokawa T, Tanaka T, Yoshino T, Okada H. Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene. World J Gastroenterol 2017; 23(33): 6155-6163
- URL: https://www.wjgnet.com/1007-9327/full/v23/i33/6155.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i33.6155